NKB2 Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.12 |
| 52 Week High | US$33.67 |
| 52 Week Low | US$11.13 |
| Beta | 2.19 |
| 11 Month Change | 41.09% |
| 3 Month Change | 34.80% |
| 1 Year Change | 154.35% |
| 33 Year Change | 38.84% |
| 5 Year Change | 326.92% |
| Change since IPO | 834.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| NKB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.9% | 0.8% | -0.4% |
| 1Y | 154.3% | -16.7% | 7.1% |
Return vs Industry: NKB2 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: NKB2 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| NKB2 volatility | |
|---|---|
| NKB2 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NKB2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NKB2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 319 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| NKB2 fundamental statistics | |
|---|---|
| Market cap | €4.13b |
| Earnings (TTM) | -€13.63m |
| Revenue (TTM) | €251.23m |
16.9x
P/S Ratio-311.2x
P/E RatioIs NKB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKB2 income statement (TTM) | |
|---|---|
| Revenue | US$264.79m |
| Cost of Revenue | US$30.94m |
| Gross Profit | US$233.85m |
| Other Expenses | US$248.21m |
| Earnings | -US$14.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 88.31% |
| Net Profit Margin | -5.42% |
| Debt/Equity Ratio | 127.3% |
How did NKB2 perform over the long term?
See historical performance and comparison